Stocks | | | Shares of Bank of America (NYSE: BAC) appeared to be taking a break yesterday from the decent rally higher they’ve been making in recent months. The company released their Q4 earnings before yesterday’s session and despite the headline numbers beating analyst expectations, shares gapped ... Read the Full Story |
|
From Our PartnersRoger's "Overnight Fortune" stock picks have been 8X more profitable than buy Amazon in 1997, turning a tiny $3k model portfolio into over $17M.
And he's about to give you the ticker symbol of its next pick... | | Access the Broadcast Here |
|
Stocks | | | While the broad-market S&P 500 (SPX) and Dow Jones Industrial Averages posted gains in the range of 30% the Dow Jones Transportation Average moved sideways. Generally speaking, this is not good news for Dow Theorists Read the Full Story |
|
Markets | | | Wall Street will be watching Charles Schwab’s (NYSE: SCHW) ticker tape closely today after the brokerage firm just about missed analyst expectations with their Q4 earnings, released after Thursday’s session. Read the Full Story |
|
From Our PartnersA groundbreaking new technology is expected to be in every household in America by the end of the year...
This technology has the potential to make over 266 million smartphones become obsolete forcing nearly every American to switch over to this new "5G Device". | | Click here to learn more. |
|
Stocks | | |
OrganiGram (NASDAQ:OGI) shares are up over 40% year-to-date. Most of that gain came on January 15 when the stock jumped 35% after it posted first-quarter revenue that beat analysts’ expectations. More importantly, OrganiGram’s revenue was more than double on a year-over-year basis.
Th... Read the Full Story |
|
Stocks | | |
Housing starts are a critical part of several markets. Not only are they a direct impact on the real estate market, they're also something of a bellwether of consumer confidence. After all, no one starts building a house if they're feeling shaky about their chances of holding a job. The most recen... Read the Full Story |
|
|
The Early Bird Stock Of The Day La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. | | View Today's Stock Pick |
|
